Cegedim Healthcare Solutions has been notified of a Drug Safety Update (DSU) published by the Medicines and Healthcare products Regulatory Agency (MHRA) in February 2025 relating to valproate treatment. This DSU advises that a review by two specialists is required for patients initiating valproate under 55 years of age but not for men (or males) who are already taking valproate.
Full details are available on the GOV.UK website: https://www.gov.uk/drug-safety-update/valproate-belvo-convulex-depakote-dyzantil-epilim-epilim-chrono-or-chronosphere-episenta-epival-and-syonellv-review-by-two-specialists-is-required-for-initiating-valproate-but-not-for-male-patients-already-taking-valproate
